Cargando…
Comparative Efficacy and Safety of Janus Kinase Inhibitors and Secukinumab in Patients with Active Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
BACKGROUND: Janus kinase (JAK) inhibitors and secukinumab have been demonstrated to be effective treatments for ankylosing spondylitis (AS). However, there have been no head-to-head trials comparing the effectiveness and safety characteristics of JAK inhibitors with secukinumab. This study aimed to...
Autor principal: | Lee, Young Ho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811419/ https://www.ncbi.nlm.nih.gov/pubmed/35817017 http://dx.doi.org/10.1159/000525627 |
Ejemplares similares
-
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis
por: Weng, Chenghua, et al.
Publicado: (2021) -
Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022) -
Association Between Protein Tyrosine Phosphatase Non-Receptor Type 22 (PTPN22) Polymorphisms and Risk of Ankylosing Spondylitis: A Meta-analysis
por: Meng, Xiantao, et al.
Publicado: (2017) -
Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016) -
Secukinumab: A Review in Ankylosing Spondylitis
por: Blair, Hannah A.
Publicado: (2019)